Elisabeth-Tweesteden Ziekenhuis

Running trials

• Recruiting

  Discontinuation of Disease-modifying Anti-rheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients Also Using TNF Inhibitors

  NCT07802678· Phase 4· Source

• Active, not recruiting

  A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.

  2023-503298-39-00· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Source

• Recruiting

  The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease

  NCT07680335· Source

• Recruiting

  REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases

  NCT07160231· Phase 4· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· Source

• Recruiting

  Perioperative SDD to Prevent Infectious Complications After Esophagectomy

  NCT05865743· Phase 3· Source

• Recruiting

  VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

  NCT06257706· Phase 4· Source

• Active, not recruiting

  Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)

  NCT04225312· Phase 4· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  NCT06203210· Phase 3· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· Source

• Recruiting

  The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

  NCT06082492· Source

• Recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  NCT06233461· Phase 2· Source

• Recruiting

  Omentum Preservation Versus Complete Omentectomy in Gastrectomy for Gastric Cancer

  NCT05180864· Source

• Recruiting

  Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

  NCT05950945· Phase 3· Source

• Recruiting

  Peroperative Administration of Tranexamic acid in gastric bypass to reduce haemorrhage in patients with morbid obesity

  NCT05464394· Phase 3· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Recruiting

  What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?

  NCT04436978· Phase 4· Source

• Active, not recruiting

  SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)

  NCT05392608· Phase 2· Source

• Active, not recruiting

  Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)

  NCT05318612· Phase 3· Source

• Active, not recruiting

  A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

  NCT05197049· Phase 3· Source

• Recruiting

  Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

  NCT04774159· Phase 3· Source

• Recruiting

  Induction Chemotherapy for Locally Recurrent Rectal Cancer

  NCT04389086· Phase 3· Source

• Recruiting

  Prospective Bladder Cancer Infrastructure (ProBCI)

  NCT04503577· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Source

• Recruiting

  TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

  NCT04294927· Source

• Recruiting

  The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.

  NCT03861299· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· Phase 3· Source

• Active, not recruiting

  Multicentric Randomised Trial for Resectable Gastric Cancer

  NCT02931890· Phase 2· Source

• Active, not recruiting

  Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.

  NCT03348150· Phase 3· Source

• Active, not recruiting

  Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

  NCT01792934· Source

• Recruiting

  Prospective Data Collection Initiative on Colorectal Cancer

  NCT02070146· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Colorectal cancer2 recruiting
• Coronary artery disease2 recruiting
• Crohn's disease2 recruiting
• Gastric and esophageal cancer2 recruiting
• Rheumatoid arthritis2 recruiting
• Stroke2 recruiting
• Alzheimer disease1 recruiting
• Ankylosing spondylitis1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Glioblastoma1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· Source

• Completed

  Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

  NCT05672199· Phase 2· Source

• Completed

  A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

  NCT05737940· Phase 2· Source

• Completed

  Safety and Performance of INVICTA Ventricular DF4 LEADS With Active Fixation-(APOLLO)

  NCT04590144· Source

• Active, not recruiting

  Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04384484· Phase 3· Source

• Completed

  Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands

  NCT03783429· Phase 4· Source